Biosimilars, Year One: FDA Estimates 2 Applications, 1,720 Hours Of Work
Executive Summary
The agency’s expectation is that there will be a limited number of biosimilar applications, but the applicants will need as much time as traditional BLA sponsors to prepare their submissions.
You may also be interested in...
Biosimilars: Exclusivity Guidance Possible; Head-To-Head Comparison Studies Sinking In
FDA’s Denise Esposito says that in many cases the agency will require biosimilar sponsors to conduct head-to-head comparison studies with the reference product.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.